Vyriad, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.vyriad.com
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 2 Trial of Voyager V1 in Combination with Cemiplimab in Cancer Patients
- Conditions
- Head and Neck Squamous Cell CarcinomaColo-rectal CancerMelanoma
- Interventions
- Biological: VV1
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Vyriad, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT04291105
- Locations
- 🇺🇸
Mayo Clinical, Jacksonville, Florida, United States
🇺🇸City of Hope Medical Center, Durate, California, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
- Conditions
- Solid TumorNon Small Cell Lung CancerNeuroendocrine CarcinomaRenal Cell Carcinoma (RCC)
- Interventions
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Vyriad, Inc.
- Target Recruit Count
- 86
- Registration Number
- NCT03647163
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy
- Conditions
- Urothelial Carcinoma
- First Posted Date
- 2017-05-31
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Vyriad, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03171493
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Ochsner Health, New Orleans, Louisiana, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors
- Conditions
- Malignant Solid Tumour
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Vyriad, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT02923466
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab
- Conditions
- Recurrent Non-Small Cell Lung Cancer
- First Posted Date
- 2016-09-29
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Vyriad, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT02919449
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States